Refine by
Metastatic Tumor Articles & Analysis
26 news found
” At data cutoff (July 16, 2022), 51 of 52 patients enrolled in the Phase 2 expansion phase of the trial had received at least one dose of tulmimetostat in the following cohorts: metastatic castration-resistant prostate cancer, lymphoma, BAP1-mutated mesothelioma, ARID1A-mutated ovarian clear cell carcinoma, ARID1A-mutated endometrial carcinoma and ARID1A-mutated ...
ATG-037 is Antengene’s oral small molecule CD73 inhibitor; KEYTRUDA® (pembrolizumab) is MSD’s anti-PD-1 therapy The clinical trial collaboration will focus on evaluating ATG-037 as a monotherapy and in combination with KEYTRUDA® for the treatment of locally advanced or metastatic solid tumors The study of ATG-037 monotherapy started ...
-The STAMINA-001 study will evaluate ATG-037 as a monotherapy and in combination with the immune checkpoint inhibitor (ICI), pembrolizumab, to determine the safety, pharmacology, and preliminary efficacy in patients with locally advanced or metastatic solid tumors. Shanghai and Hong Kong, PRC, November 2, 2022 -- Antengene Corporation Limited ...
PSMA expression is significantly higher in prostate cancer cells, increasing with the development of the tumor and as it metastasizes (when cancer cells break away from the primary tumor and travel through the blood or lymph system and form new tumors – metastatic tumors – in other parts of the body). ...
The efficacy proof of concept is an 85-95% reduction in primary and metastatic tumor burden in multiple animal models in the absence of adverse effects. ...
“We are pleased with the progress of this next-generation biologic candidate, from discovery to clinical development for patients with advanced or metastatic solid tumors,” said Bill Newell, Chief Executive Officer of Sutro. ...
This is an invasive surgical procedure used to determine metastatic spread of the cancer for staging purposes. In approximately 80% of the surgeries, the biopsy comes back negative for metastasis and does not further impact the patient pathway. The Merlin Test provides a more personalized insight on the metastatic propensity of the tumor, and how ...
Technology is a first-of-its kind molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone Study will examine the safety and efficacy of ZetaMetTM in the treatment of metastatic bone lesions as part of advanced stage cancer therapy Study is targeting Stage 4 breast cancer patients who have metastatic lesions in their spinal vertebrae ...
Through this effort, GI Innovation and AstraZeneca aim to treat patients with metastatic and advanced solid tumors who have limited treatment options available to them. ...
Actym Therapeutics today announced that ACTM-838 has been selected as a lead clinical development candidate for the treatment of solid tumors. ACTM-838 is based on the company's immunotherapy platform called STACT (S. ...
SEATTLE, Nov. 10, 2021 (GLOBE NEWSWIRE) -- SEngine Precision Medicine and Dana-Farber Cancer Institute today announced a collaboration to bring SEngine’s PARIS® Test to adult and pediatric patients with primary or metastatic solid-tumor central nervous system (CNS) cancers. The collaboration aims to provide patients and their oncologists with more ...
PsiOxus is developing this agent as one of several products within its T-SIGn® portfolio of vectors that combine systemic delivery with localized production of powerful transgene payloads to allow the selective re-engineering of both primary and metastatic tumors. The data to be presented at the ESMO Congress show that IV delivery of NG-350A results in ...
Canady will present results from their FDA-approved Phase I Clinical Trial evaluating Cold Atmospheric Plasma for the treatment of Stage IV, Recurrent, Metastatic Solid tumors (FDA IDE #190165) and their recent discovery identifying the mechanism in which Canady Helios™ Cold Plasma induces apoptosis in breast cancer. ...
Only 20%-30% of patients with liver tumors are eligible for surgical resection due to the presence of multiple tumors, underlying poor liver function, or general health issues limiting the success of surgery. Primary liver tumors were the third leading cause of tumor related death worldwide in 2020, with approximately 906,000 ...
” Prior years’ Rosenman Innovators include Koya Medical, which recently received FDA clearance for the Dayspring™ active compression therapy system to treat lymphedema; GT Medical, which recently enrolled its first patient in a clinical trial evaluating GammaTile® Therapy in patients with metastatic brain tumors; and EMME, maker of the EMME ...
Prior years' Rosenman Innovators include Koya Medical, which recently received FDA clearance for the Dayspring™ active compression therapy system to treat lymphedema; GT Medical, which recently enrolled its first patient in a clinical trial evaluating GammaTile® Therapy in patients with metastatic brain tumors; and EMME, maker of the EMME Smart Case for ...
The study is designed to evaluate the safety and efficacy of the HistoSonics’ platform technology, which uses the novel science of histotripsy and the mechanical properties of therapeutic focused ultrasound, to destroy unwanted tissue, including targeted primary and metastatic liver tumors, without the need for incisions or invasiveness. ...
” About Tumor Treating Fields Tumor Treating Fields, or TTFields, are electric fields that disrupt cancer cell division. ...
Single IV cycle of PsiOxus’ T-SIGn vector enabled an otherwise non-effective dose of CAR-T cell therapy to clear primary and metastatic tumors in vivo Reprogramming of the tumor microenvironment using T-SIGn vectors could enable a variety of CAR-T therapies to overcome limitations in solid tumors Data is currently being ...
This CRL does not impact any current approved indications for KEYTRUDA, including the indication for KEYTRUDA in combination with chemotherapy for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (Combined Positive Score [CPS] ≥10), as determined by an FDA-approved test. ...